{
    "clinical_study": {
        "@rank": "19913", 
        "arm_group": [
            {
                "arm_group_label": "LY2605541 (Part A)", 
                "arm_group_type": "Experimental", 
                "description": "0.5 units per kilogram (U/kg) LY2605541 subcutaneously (SQ) once daily for 15 days. Participants will remain on their regular physician-prescribed mealtime insulin. Part A involves 3 clamp procedures on Days 8, 11 and 14."
            }, 
            {
                "arm_group_label": "Glargine (Part A)", 
                "arm_group_type": "Active Comparator", 
                "description": "0.5 U/kg insulin glargine SQ once daily for 15 days. Participants will remain on their regular physician-prescribed mealtime insulin. Part A involves 3 clamp procedures on Days 8, 11 and 14."
            }, 
            {
                "arm_group_label": "LY2605541 + Exercise (Part B)", 
                "arm_group_type": "Experimental", 
                "description": "0.5 U/kg LY2605541 SQ once daily for 6 days. Exercise challenge on Day 17 or 20. Participants will remain on their regular physician-prescribed mealtime insulin."
            }, 
            {
                "arm_group_label": "LY2605541 (Part B)", 
                "arm_group_type": "Experimental", 
                "description": "0.5 U/kg LY2605541 SQ once daily for 6 days.  Participants will remain on their regular physician-prescribed mealtime insulin."
            }, 
            {
                "arm_group_label": "Glargine + Exercise (Part B)", 
                "arm_group_type": "Active Comparator", 
                "description": "0.5 U/kg insulin glargine SQ once daily for 6 days. Exercise challenge on Day 17 or 20. Participants will remain on regular physician-prescribed mealtime insulin."
            }, 
            {
                "arm_group_label": "Glargine (Part B)", 
                "arm_group_type": "Active Comparator", 
                "description": "0.5 U/kg insulin glargine SQ once daily for 6 days. Participants will remain on regular physician-prescribed mealtime insulin."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to measure how much of the study drug or insulin glargine gets\n      into the blood stream and how long it takes the body to get rid of it. The effect of\n      exercise will also be evaluated.\n\n      This study has two parts. In Part A, each participant will receive a daily injection of\n      LY2605541 or insulin glargine for about 15 days. Some participants may continue into Part B.\n      In Part B, participants will receive a daily injection of LY2605541 or insulin glargine with\n      or without exercise. Part B lasts about 6 days.\n\n      Participants will remain on their regular physician-prescribed meal time insulin throughout\n      the study."
        }, 
        "brief_title": "A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Diabetes Mellitus, Type 1", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Are males or females that have had a diagnosis of Type I Diabetes Mellitis (T1DM) for\n             at least 12 months and are receiving multiple daily insulin injections. Total daily\n             insulin dose <1.2 units per kilogram per day (U/kg/day); daily basal dose >0.2\n             U/kg/day\n\n          -  Female participants are women of child-bearing potential who test negative for\n             pregnancy at the time of enrollment based on a urine pregnancy test and agree to use\n             a reliable method of birth control during the study\n\n          -  Have a body mass index (BMI) of 18 to 30 kilograms per meter square (kg/m^2),\n             inclusive\n\n          -  Have a fasting c-peptide <0.3 nanomoles per liter (nmol/L)\n\n          -  Have a hemoglobin A1c (HbA1c) < 9% at screening\n\n        Participants with T1DM are eligible for enrollment in Part B of the study only if they\n        meet all of the following criteria:\n\n          -  Have a maximal oxygen uptake (VO2 max) of \u2265 25 milliliters (ml) of oxygen per\n             kilogram per minute (O2/kg/min) (for women) or \u2265 30 ml O2/kg/min (for men)\n\n          -  Perform regular physical cardiorespiratory activity to achieve an average total\n             energy expenditure of \u2265 500 metabolic equivalent of task (MET)-minutes per week\n             during the last 3 months prior to screening\n\n        Exclusion Criteria:\n\n          -  Have known allergies to LY2605541, insulin glargine, related compounds or any\n             components of the formulation\n\n          -  Have a history of or current cardiovascular, respiratory, hepatic, renal,\n             gastrointestinal, endocrine (apart from type 1 diabetes), hematological, or\n             neurological disorders capable of significantly altering the absorption, metabolism,\n             or elimination of drugs; of constituting a risk when taking the study medication; or\n             of interfering with the interpretation of data\n\n          -  Have had episodes of severe hypoglycemia in the past 6 months (severe hypoglycemia is\n             defined as having neurological symptoms consistent with neuroglycopenia and having\n             required assistance in treatment by a second party)\n\n          -  Have a history of hypoglycemia unawareness\n\n          -  Regular use or intended use of any over-the-counter or prescription medications or\n             nutritional supplements that may affect blood glucose or the body's sensitivity to\n             insulin or that promote weight loss within 14 days prior to dosing\n\n          -  Have an average weekly alcohol intake that exceeds 21 units per week (males up to age\n             65) and 14 units per week (males over 65 and females), or are unwilling to comply\n             with study requirements regarding alcohol consumption\n\n          -  Currently smokes > 5 cigarettes per day, or are unwilling to comply with study\n             requirements regarding smoking or use of tobacco products\n\n          -  Have a hemoglobin level <8.0 millimoles per liter (mmol/L) (male) or <6.4 mmol/L\n             (female) at screening\n\n          -  Are currently participating in a weight loss program or plan to do so during the\n             course of the study\n\n          -  Are receiving chronic (lasting longer than 14 consecutive days) systemic\n             glucocorticoid therapy (excluding topical, intra-articular, and intraocular\n             preparations) or have received such therapy within the 4 weeks before dosing\n\n          -  Have fasting triglycerides >400 milligrams per deciliter (mg/dL) (4.52 mmol/l)\n\n          -  Have previous history or family history of deep vein thrombosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "76", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01784211", 
            "org_study_id": "14183", 
            "secondary_id": "I2R-MC-BIAW"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LY2605541 (Part A)", 
                    "LY2605541 + Exercise (Part B)", 
                    "LY2605541 (Part B)"
                ], 
                "description": "Administered SQ", 
                "intervention_name": "LY2605541", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Glargine (Part A)", 
                    "Glargine + Exercise (Part B)", 
                    "Glargine (Part B)"
                ], 
                "description": "Administered SQ", 
                "intervention_name": "Insulin Glargine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "6", 
        "official_title": "The Pharmacokinetic and Pharmacodynamic Intra-subject Variability of LY2605541 and the Effect of Exercise on LY2605541 Pharmacokinetics in Patients With Type 1 Diabetes Mellitus", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Part A: Pharmacokinetics: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUC\u03c4) of LY2605541 and Insulin Glargine: Intra-Participant Variability", 
                "safety_issue": "No", 
                "time_frame": "Part A: Predose up to Day 15"
            }, 
            {
                "measure": "Part A: Pharmacokinetics: Maximum Drug Concentration (Cmax) of LY2605541 and Insulin Glargine: Intra-Participant Variability", 
                "safety_issue": "No", 
                "time_frame": "Part A: Predose up to Day 15"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01784211"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Part A: Pharmacodynamics: Total Amount of Glucose Infused Over the Duration of the Clamp (Gtot): Intra-Participant Variability", 
                "safety_issue": "No", 
                "time_frame": "Part A: Predose up to Day 15"
            }, 
            {
                "measure": "Part B: Pharmacokinetics: AUC\u03c4 of LY2605541 and Insulin Glargine: Exercise Versus Non-Exercise", 
                "safety_issue": "No", 
                "time_frame": "Part B: Day 17 to 21"
            }, 
            {
                "measure": "Part B: Pharmacokinetics: Cmax of LY2605541 and Insulin Glargine: Exercise Versus Non-Exercise", 
                "safety_issue": "No", 
                "time_frame": "Part B: Day 17 to 21"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}